Journal
CLINICAL NEUROPHARMACOLOGY
Volume 35, Issue 2, Pages 77-80Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0b013e31824644e6
Keywords
natalizumab; multiple sclerosis; EDSS; annual relapse rate; real-life
Categories
Funding
- Merck Serono
- Biogen
- Merck Serono
- Bayer Health Care
- Biogen Idec
- Novartis
- Teva Pharmaceuticals
Ask authors/readers for more resources
Objectives: Therapy for relapsing-remitting multiple sclerosis with natalizumab (Tysabri; Biogen Idec) has been shown to be effective in the reduction of the clinical relapse rate and disability progression. However, real-life longitudinal data, including years before baseline, are rare. Methods: An observational single-center study was carried out. We analyzed data from 64 consecutive patients with multiple sclerosis. Results: After 1 year of treatment (n = 64), score on the Expanded Disability Status Scale (EDSS) decreased by 0.47 points (P = 0.047) and the annualized relapse rate (ARR) decreased by 82% (P < 0.001). After 2 years (n = 41), EDSS score was still reduced by 0.28 (not significant) and ARR was reduced by 69% (P < 0.001). After 3 years (n = 23), EDSS score was reduced by 0.26 (not significant), and ARR was reduced by 77% (P < 0.001). Reduction of EDSS score and ARR did not depend on baseline ARR (1-2 vs 92) or EDSS score and was not biased by exceptional high disease activity or relapses around baseline. Conclusions: These real-life data reinforce that natalizumab is effective over years, reduces ARR, and stabilizes EDSS score independent of baseline ARR, baseline EDSS score, or baseline treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available